One of the goals of Pharmacovigilance is to detect adverse effects of drug use, and to achieve this, the science of drug safety is acting on very early phases of drug development. The challenge is to establish a causal relationship between a drug, or a class of drugs, and events with low incidence and/or with a non-obvious temporal association, like the development of a malignancy after drug use. This presentation provided a review of the role of immunosuppressive drugs on the development of lymphomas, and addressed the balance between the risk and the benefits of this therapy.
William Rotea, Pharm D
Bayer Healthcare, Sao Paula, Brazil